



January 21, 2015

## **ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2015 Financial Results**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 30, 2015, to discuss ImmunoGen's financial results for the three-month period ended December 31, 2014, the second quarter of its 2015 fiscal year. Management will also provide an update on the Company.

To access the live call by phone, dial 913-312-0977; the conference ID is 8510777. The call also may be accessed through the Investors section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay of the call will be available at the same location through February 13, 2015.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product approved with ImmunoGen's ADC technology is Roche's Kadcyla<sup>®</sup>. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in the clinic through the Company's partnerships with Amgen, Bayer HealthCare, Biotest, Novartis and Sanofi. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyla<sup>®</sup> is a registered trademark of Genentech, Inc., a member of the Roche Group.

For Investors:  
ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
[info@immunogen.com](mailto:info@immunogen.com)

or  
For Media:  
Pure Communications, Inc.  
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media